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SummAry – The impact of the metabolic syndrome/insulin resistance syndrome (mS/irS) 
on the severity and prognosis of acute St elevation myocardial infarction (Stemi) treated with 
primary percutaneous coronary intervention (PCi) was assessed using the American Association of 
Clinical endocrinologists and American College of endocrinology (AACe/ACe) definition from 
2003. A total of 385 patients having suffered acute Stemi and treated with primary PCi over a 
two-year period were divided into two groups (with and without mS/irS) and compared according 
to the parameters of severity (clinical, laboratory, echocardiography, coronary angiography parame-
ters and complications) and prognosis using major adverse cardiovascular events (mACe) during 
the six-month follow-up of acute Stemi. in comparison with control group, the mS/irS group 
of patients had worse or similar results of almost all study parameters of severity (hospital days 6.5 
vs. 6.5, cardiogenic shock 2.9% vs. 2.6%, cardiac arrest 6.8% vs. 5.2%, reinfarction 0.5 vs. 1.6%) 
and prognosis (total mACe 30.7 vs. 30.7%), however, none of the differences reached statistical 
significance. it is concluded that the unexpected lack of such differences in mS/irS could be due to 
the absence of waist-to-hip ratio in the definition and other open questions in metabolic syndrome 
in general.  
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Introduction
The concurrence of metabolic risk factors for en-
dothelial dysfunction and atherosclerotic cardiovas-
cular disease, which include abdominal obesity, hy-
perglycemia, dyslipidemia, and hypertension, suggests 
the existence of metabolic syndrome. Other names 
used for this constellation of findings are syndrome 
X, insulin resistance syndrome, ‘deadly quartet’, or 
obesity dyslipidemia syndrome1,2. According to a re-
cent paper by mottillo et al.3, the metabolic syndrome 
is associated with a 2-fold increase in cardiovascular 
outcomes and 1.5-fold increase in all-cause mortality. 
Studies are needed to investigate whether or not the 
prognostic significance of the metabolic syndrome ex-
ceeds the risk associated with the sum of its individual 
components. furthermore, additional studies should 
elucidate the mechanisms by which the metabolic 
syndrome increases cardiovascular risk. The overall 
prevalence of metabolic syndrome is estimated to be 
around 20% with an age-dependent increase and in-
crease over time4.
There are several definitions of the metabolic syn-
drome1-3,5. The criteria provided for the definition of 
the metabolic syndrome/insulin resistance syndrome 
(mS/irS) according to the American Association of 
Clinical endocrinologists/American College of en-
docrinology (AACe/ACe)6,7 are:
194 Acta Clin Croat,  Vol. 50,   No. 2,  2011
Z. babić et al. metabolic syndrome in acute myocardial infarction
1) triglycerides >1.69 mmol/l,
2) hdl cholesterol <1.04 mmol/l in men and <1.29 
in women,
3) elevated blood pressure (≥130/85 mm hg), 
4) 2-hour post-glucose challenge >7.78 mmol/l and 
fasting glucose between 6.11 and 7.00 mmol/l,
5) overweight/obesity (body mass index ≥25 kg/m2), 
and
6) other risk factors including:
- family history of type 2 diabetes, hypertension, 
or CVd,
- polycystic ovary syndrome,
- sedentary lifestyle,
- advancing age, and
- ethnic groups having high risk for type 2 diabe-
tes or cerebrovascular disease.
diagnosis depends on clinical judgment with two 
or more of the first four criteria listed above. This def-
inition has been designed to help physicians predict 
and prevent serious complications from a number of 
related conditions grouped in the cluster, even if the 
underlying pathophysiology may not be completely 
understood. The differences from other definitions 
may be summarized as follows: 1) the mS/irS is used 
to describe the cluster of abnormalities that are more 
likely to occur in insulin resistant/hyperinsulinemic 
individuals; 2) the mS/irS is differentiated from type 
2 diabetes; 3) body mass index, rather than waist cir-
cumference, is used as the index of obesity, and viewed 
as a physiological variable that increases insulin resis-
tance, rather than as a criterion for the diagnosis of 
mS/irS; 4) ethnicity is introduced as an important 
risk factor for insulin resistance, and non-Caucasian 
ancestry identified as an increasing risk of mS/irS; 
5) other factors have been identified that increase the 
risk of developing mS/irS, including family history 
of type 2 diabetes, hypertension, cerebrovascular dis-
ease, polycystic ovary syndrome, gestational diabetes, 
and acanthosis nigricans; and 6) fasting plasma glu-
cose concentrations are used to identify individuals 
with type 2 diabetes, and the plasma glucose concen-
tration 2 h after 75-g oral glucose load is introduced as 
a more sensitive measure of the risk of mS/irS.  
using the AACe/ACe6,7 definition for mS/irS, 
the main objectives of this study were: 
- to calculate the incidence of mS/irS among con-
secutive patients with acute St-elevation myo-
cardial infarction (Stemi) treated with primary 
percutaneous coronary intervention (PCi) and to 
compare the results with literature data;
- to evaluate the severity of heart disease and acute 
Stemi in patients with mS/irS and to compare 
the results with patients without the syndrome; 
and
- to evaluate the prognosis of acute Stemi in pa-
tients with mS/irS and to compare the results 
with patients without the syndrome. 
Patients and Methods
Study population
This retrospective study included 385 consecutive 
patients having suffered acute Stemi and treated 
with primary PCi in Kerckhoff heart Center, bad 
nauheim, Germany, over a two-year period. data 
were collected from hospital registry. The diagnosis of 
Stemi was established and primary PCi performed 
using the european Cardiac Society criteria8,9. in 
brief, patients with an episode of chest pain within 
the last 48 hours and St-elevation on electrocardi-
ography (eCG) in at least two consecutive leads were 
included. 
Methods
After primary PCi patients were hospitalized at 
cardiology department with continuous monitoring 
including clinical, eCG, laboratory and echocar-
diography. Six months after discharge, the authors 
collected data on major adverse cardiovascular events 
(mACe) (restenosis, reinfarction, cardiac and non-
cardiac rehospitalization, mortality, coronary artery 
bypass graft (CAbG) and cerebrovascular insult (CVi 
rate)) during patient examination, by checking medi-
cal documentation or by telephone contact with pa-
tient family members or family physicians. 
using the AACe/ACe6,7 definition of mS/irS, 
study patients were divided into two groups (with and 
without mS/irS) and compared according to the se-
verity of their heart disease and prognosis. The sever-
ity of heart disease and acute Stemi were estimated 
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using clinical findings (angina pectoris before primary 
PCi, dyspnea, all eCG verified rhythm abnormali-
ties, heart failure, cardiogenic shock, cardiac arrest 
and artificial respiration), cardiac laboratory marker 
values (creatine phosphokinase (CPK), cardiac tro-
ponin t (ctnt)), echocardiography (left ventricular 
ejection fraction (lVef)) and coronarography find-
ings (culprit vessel, number of significantly narrowed 
coronary arteries, diameter and length of stents) and 
number of hospital days. The prognosis was estimated 
using intrahospital reinfarction and re-PCi, as well as 
mACe during six-month follow-up. 
Angiography and PCi were performed by the 
standard technique on a monoplane system (Axiom 
Artis, Siemens, erlangen, Germany) as recommended 
in current guidelines9. Patients received 70 ie/kg un-
fractionated heparin, 500 mg aspirin, a loading dose 
of 600 mg clopidogrel and in most cases a GPiib/iiia 
inhibitor. Serum biomarkers were assessed as com-
mercially available. echocardiography was performed 
according to the clinical standard and in accordance 
with recommendations related to current echocar-
diography guidelines10.   
Statistical analysis
Statistical analysis was performed by using the 
SPSS for windows 15 software. nominal (categori-
cal) variables were analyzed by using Pearson χ2-test 
and fisher’s exact test, and quantitative variables by 
using mann-whitney test. The level of significance 
was set at P<0.05. 
Ethical standards
The study was performed in accordance with ethi-
cal standards laid down in the declaration of helsin-
ki and was approved by the appropriate institutional 
review committee.
Results
The mean age of study patients was 63.0 years and 
70.3% of them were male. The anterior myocardial 
wall was affected in 41.1% and inferior wall in 58.9% 
of study patients. Out of 385 patients, 192 patients 
fulfilled the criteria for mS/irS (men 50.9% and 
women 37.5%), while 193 patients did not meet these 
Table 1. Severity of acute ST-elevation myocardial infarction





Angina pectoris (%) 95.1 93.3 0.172
dyspnea (%) 3.9 8.8 0.065
hospital days 6.48 (±4.31) 6.48 (±4.59) 0.709
intrahospital
complications
rhythm abnormalities (%) 3.9 3.6 0.785
heart failure (%) 1.0 1.0 1.000
Cardiogenic shock (%) 2.9 2.6 1.000
Cardiac arrest (%) 6.8 5.2 0.990
mechanical ventilation (%) 8.7 5.7 0.325
reinfarction (%) 0.5 1.6 0.623
re-PCi* (%) 2.1 2.1 1.000
laboratory mean maximal cardiac troponin t (ng/ml) 4.00 (±3.40) 4.46 (±3.21) 0.657mean maximal creatinine phosphokinase (u/l) 1619.7 (±1475.4) 1928.7 (±2166.3) 0.399
echocardiography mean lVef** (%) 45.65 (±9.79) 45.69 (±9.53) 0.991
Coronarography
mean number of stenosed vessels 1.69 (±0.87) 1.74 (±0.92) 0.619
mean stent diameter (mm) 3.28 (±0.40) 3.21 (±0.39) 0.118
mean stent length (mm) 14.39 (±4.93) 14.96 (±4.51) 0.214
*re-PCi = repetition of percutaneous coronary intervention; **lVef =  left ventricular ejection fraction
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criteria. There were no statistically significant age or 
sex differences between the two patient groups. 
data on the severity of acute Stemi and progno-
sis in both patient groups are shown in tables 1 and 
2, respectively. Patients with mS/irS had similar or 
worse results on all severity parameters except for the 
incidence of dyspnea, reinfarction rate, cardiac labo-
ratory markers (ctnt and CK), and the number and 
length of coronary artery stenosis. The same held for 
the parameters of prognosis except for the reinfarc-
tion rate. none of these differences reached statistical 
significance.
Discussion
most people with metabolic syndrome suffer 
thrombotic complications superimposed to athero-
sclerotic and inflammatory arterial vascular lesions. 
Altered cardiac remodeling together with altered 
adhesion and coagulation mechanisms appears suit-
able to explain decreased functional performance of 
infarcted organs, and decreased success of acute (re-
duced fibrinolytic response, no reflow phenomenon) 
and long term intervention strategies for vessel paten-
cy (PCi, CAbG) in these patients. That is why stud-
ies revealed high incidence of metabolic syndrome in 
patients with acute myocardial infarction (Ami), as 
well as more serious findings and prognosis of Ami 
in these patients11,12. investigators mostly used criteria 
for metabolic syndrome established by the national 
Cholesterol education Program expert panel on de-
tection, evaluation, and treatment of high blood cho-
lesterol in adults (Adult treatment Panel iii) (nCeP 
AtP iii)5. There are no reports evaluating AACe/
ACe definition6,7 using coronary artery disease. 
using nCeP AtP iii criteria, patients with meta-
bolic syndrome had two- to threefold increased risk of 
subclinical or clinically overt cardiovascular disease. 
using these criteria, yilmaz et al.13 and Zeller et al.14 
found metabolic syndrome in 49% and 46% of Ami 
patients without St-elevation and unselected popula-
tion of Ami patients, respectively, significantly more 
common in women. two thirds of young patients 
with premature myocardial infarction had metabolic 
syndrome15. Similar incidence of mS/irS was found 
in the present study, with a slightly higher incidence 
in men.
Patients with metabolic syndrome had increased 
infarct size, more extensive coronary artery disease, 
and poor myocardial perfusion grade13,16-18. bohmer et 
al.19 found no association of the presence of metabolic 
syndrome with related biomarkers or the size of myo-
cardial infarction. in this study, lower cohort serum 
concentrations of cardiac markers (ctnt, CK) and 
less extended coronary artery disease were recorded 
in patients with mS/irS, however, without statisti-
cal significance. According to Piatti et al.18, insulin 
resistance is an independent predictor of early in-
stent restenosis, which was not found in the present 
study (the same incidence of early in-stent restenosis). 
however, a higher incidence of late in-stent restenosis 
was found in patients with mS/irS. According to lit-
erature data20,21, metabolic syndrome is also a strong 
predictor of recurrent ischemic coronary events, but 
without correlation with either early or re-infarction 
during follow up in the present study. metabolic 
Table 2. Prognosis of acute ST-elevation myocardial infarction




reinfarction (%) 1.4 1.6 0.623
restenosis (%) 17.5 13.3 0.382
rehospitalization (cardiac) (%) 27.1 25.9 0.624
rehospitalization (non-cardiac) (%) 7.2 6.7 0.527
Cerebrovascular insult (%) 1.9 0.5 0.372
urgent CAbG** 1.0 0.0 –
mortality (%) 6.3 6.2 0.990
total (%) 30.7 30.7 1.000
*mACe = major adverse cardiovascular events; **CAbG = coronary artery bypass graft
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syndrome appeared to be associated with worse in-
hospital complications and outcome, especially with a 
higher risk of severe heart failure14,21,22. results of the 
present study suggested a higher incidence of rhythm 
abnormalities, cardiogenic shock, and cardiac arrest 
in mr/irS group (without statistical significance), 
while the incidence of heart failure and the mean left 
ventricular ejection fraction were the same in both pa-
tient groups. 
using metabolic score as a simple metabolic risk 
marker, raposo et al.23 found a statistically signifi-
cant relation between this score and outcome at one-
year follow up after non-St elevation acute coronary 
syndromes. using the nCeP AtP iii5 definition of 
metabolic syndrome, iribaren et al.24 conclude that the 
presence of this syndrome imparts a high risk of early-
onset clinical coronary disease, but the prognostic in-
formation associated with the syndrome is not greater 
than the sum of its parts. The authors of this article 
found the same incidence of mACe in general in the 
two groups of study patients during six-month follow 
up, with nonsignificant differences in some compo-
nents. 
using the AACe/ACe definition for mS/irS, 
the authors did not find the expected significant in-
fluence of this syndrome on the severity and prognosis 
during six-month period in patients having suffered 
acute Stemi and treated with primary PCi. from 
the interventional cardiologists’ point of view, one of 
the explanations could be that early invasive treatment 
of acute Stemi attenuates the risk of metabolic syn-
drome. however,  there are several open questions in 
metabolic syndrome in general, i.e. the lack of clarity 
of definition, multiple different patient phenotypes, 
the lack of consistent evidence base, unclear pathogen-
esis uniting the syndrome components, and the fact 
that cardiovascular risk associated with the syndrome 
is not greater than the sum of its individual compo-
nents24-27. Among all these issues, anthropometry as 
an additional problem seems to be one of the major 
ones in the AACe/ACe definition6,7 body mass in-
dex used in this definition is an inferior anthropomet-
ric parameter in comparison to waist circumference or 
waist-to-hip ratio in verification of abdominal obesity 
and cardiovascular risk28,29. That is why it is neces-
sary to emphasize the importance of the waist and hip 
circumference measurement in all patients with coro-
nary disease, especially in risk stratification of patients 
with Ami. Also, the mS/irS diagnosis dependence 
on clinical judgment may result in lower accuracy and 
investigation of different patient populations in dif-
ferent studies.
in conclusion, evaluating the AACe/ACe6,7 defi-
nition for mS/irS in patients with acute Stemi 
treated with primary PCi, the authors found no sta-
tistically significant differences in the severity and 
prognosis between patients with and without the syn-
drome. The main reasons for such unexpected results 
may lie in many open questions in this definition (pri-
marily the absence of waist-to-hip ratio) and meta-
bolic syndrome in general.
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Sažetak
metAbOliČni SindrOm i iShOd u bOleSniKA S AKutnim infArKtOm miOKArdA 
Z. Babić, M. Pavlov, N. Bulj, V. Nikolić Heitzler, V. Mitrović, Ch. Hamm i M. Weber 
istraživao se utjecaj metaboličnog sindroma/sindroma inzulinske rezistencije (mS/Sir) koristeći definiciju American 
Association of Clinical Endocrinologists i American College of Endocrinology (AACe/ACe) iz 2003. na težinu i prognozu 
akutnog infarkta miokarda s elevacijom St spojnice (Stemi) liječenog primarnom perkutanom intervencijom (pPCi). 
ukupno 395 bolesnika koji su preboljeli akutni Stemi i bili liječeni pomoću pPCi u dvogodišnjem razdoblju podijeljeno 
je u dvije skupine (s mS/Sir i bez njih) i uspoređeno prema parametrima težine (klinički, laboratorijski, ehokardiograf-
ski, koronarografski, komplikacije) i prognoze koristeći velike neželjene kardiovaskularne događaje (mACe) tijekom 
šestomjesečnog praćenja akutnog Stemi. Skupina bolesnika s mS/Sir u usporedbi s kontrolnom skupinom imala je 
uglavnom lošije ili jednake rezultate težine (dani u bolnici 6,5:6,5, kardiogeni šok 2,9%:2,6%, srčani zastoj 6,8%:5,2%, 
reinfarkt 0,5%:1,6%) i prognoze (ukupno mACe 30,7%:30,7%), no niti jedna od razlika nije dosegla statističku značaj-
nost. Zaključuje se kako bi izostanak takvih očekivanih razlika u mS/Sir mogao biti posljedica isključenja omjera struka 
i kukova iz ove definicije i ostalih otvorenih pitanja u metaboličnom sindromu uopće.
Ključne riječi: Metabolični sindrom X; Infarkt miokarda

